Bevacizumab News and Research RSS Feed - Bevacizumab News and Research

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades. [More]
Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine. [More]
Simple saline solution could help alleviate chronic nosebleeds, study shows

Simple saline solution could help alleviate chronic nosebleeds, study shows

Squirting a simple saline solution into the nose twice a day could alleviate chronic nosebleeds just as effectively as spraying with any one of three different medications, reports a study published online in the Journal of the American Medical Association on Sept. 6. [More]
Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding. [More]
Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. [More]
Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. [More]
NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability. [More]
Genetic testing in women with ovarian cancer helps determine prognosis

Genetic testing in women with ovarian cancer helps determine prognosis

A study examining mutations in DNA repair genes in women with advanced ovarian cancer found that the disease remained at bay longer in women with the mutations than without, and that women having cancers with these mutations lived longer. [More]
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing. [More]
Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania. [More]
Research unveils standard front-line treatment for advanced ovarian cancer

Research unveils standard front-line treatment for advanced ovarian cancer

Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation. [More]
Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

A study published online ahead of print in the journal Medical Care shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent. [More]
PD-L1 inhibition well-tolerated, active in metastatic RCC

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings. [More]
Bevacizumab extends survival of pleural mesothelioma patients

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet. [More]
Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment. [More]
New campaign raises awareness of City of Hope's life-saving mission and impact

New campaign raises awareness of City of Hope's life-saving mission and impact

Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope. [More]
Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis. The group began at Northwestern University, Chicago, under the direction of Dr. David McPherson and he continues to lead the group. [More]
Advertisement
Advertisement